Skip Navigation LinksHome > March 2014 - Volume 36 - Issue 2 > Golden Bullet—Denosumab: Early Rapid Response of Metastatic...
Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0000000000000034
Clinical and Laboratory Observations

Golden Bullet—Denosumab: Early Rapid Response of Metastatic Giant Cell Tumor of the Bone

Demirsoy, Ugur MD*; Karadogan, Meriban MD*; Selek, Özgür MD; Anik, Yonca MD; Aksu, Görkem MD§; Müezzinoglu, Bahar MD; Corapcioglu, Funda MD*

Collapse Box

Abstract

Giant cell tumor of the bone (GCTB) is usually a benign, locally aggressive tumor with metastatic potential. Histogenesis of GCTB is unknown and a correlation has not been found between histologic and clinical course. For this reason, many authors consider its prognosis unpredictable. Lung metastasis after GCTB treatment is well known and generally has unfavorable outcome, despite varied chemotherapy regimens. Denosumab, which inhibits RANK-RANKL interaction, is a new, promising actor among targeted therapeutic agents for GCTB. In this report, we emphasize on early rapid response to denosumab in metastatic GCTB.

Copyright © 2013 by Lippincott Williams & Wilkins

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/JPHOonline

For additional oncology content, visit LWW Oncology Journals on Facebook.